Published Date: 18 Dec 2023
HIF-2 inhibitor recommended for patients who show improvement following anti-VEGF and immunotherapy.
Read Full NewsAbdominal and chest pain. Injuries. Breathing difficulty. Infections. Mental health emergencies. Those are some of the most common reasons why people go to the local emergency department.
University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more difficult to detect than ...
Cancer treatment has come a long way, but many of today's therapies still come with steep costs: not just financial, but physical and emotional too. Chemotherapy and radiotherapy remain vital tools, yet they often damage ...
1.
The Effect of Common Steroids on Cancer Treatments.
2.
Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP
3.
Improved end-of-life conversations for cancer patients are identified by a new study.
4.
Exercise may help breast cancer survivors manage weight
5.
The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.
1.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
2.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
3.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
4.
Next-Gen Cancer Therapies: Radiopharmaceuticals, Immuno-Oncology, and Biologic Breakthroughs
5.
Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation